Earnings Call Insights: Protalix BioTherapeutics (PLX) Q2 2026
Management view
- “Our results today reflect the strength of our profitable commercial partnerships, and we remain confident in our outlook for this year,” said President, CEO & Director Dror Bashan, adding, “We entered the second half of 2026 with
Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
